Alcon announced that it has made available TobraDex ST (tobramycin and dexamethasone ophthalmic suspension) for the treatment of steroid-responsive inflammatory ocular conditions where superficial ...

Tobradex ST is supplied as an ophthalmic suspension containing 3mg/mL of tobramycin and 0.5mg/mL of dexamethasone. For more information visit eyevance.com. Related News.

HUENENBERG, Switzerland — Alcon has launched TobraDex ST ophthalmic suspension in the United States, the company announced in a press release. ...

Annual market sales for Tobradex® Ophthalmic Suspension for the 12 months ending January 2022 were approximately $106 million as measured by IQVIA. Padagis President and Chief Executive Officer, ...

TOBRADEX® ST ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a ...

HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions. Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension ...

The U.S. Food and Drug Administration has approved Alcon's new drug application for a new formulation of a fixed combination of tobramycin and dexamethasone for treating inflammatory ocular ...

Amneal Receives Approval for Generic TobraDex® - Adding another complex ophthalmic product to the generics portfolio July 19, 2021 04:32 PM Eastern Daylight Time ...

Harrow, a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications for the following products:. Harrow announced its ...

ALLEGAN, Mich., March 21, 2022 /PRNewswire/ -- Padagis today announced the FDA approval and launch of an AB-rated generic version of Tobradex® Ophthalmic Suspension. Tobradex® Ophthalmic ...